An essential need exists for microarray-based experimentation and expertise required by investigators of the SPORE. in Prostate Cancer. The SPORE in Prostate Cancer Core Facility for the DNA Array is designed to provide a comprehensive resource to meet this need. There are several critical issues that face investigators using microarrays for high-throughput nucleic acid analysis that this centralized resource will address including: satisfying the need for experienced technical support and specialized equipment; quality control and trouble shooting for critical procedures to maintain consistent and reproducible technique; cost effective, equitable efficient use of shared equipment and supplies; expertise for experiment planning and data analysis; and facilitating interactions between projects and cores in the SPORE. This resource is the most efficient and cost effective means to provide these necessary research components to the multiple investigators in this SPORE that use microarray-based experiments. The overall objective of this core is to provide an efficient, high-quality, centralized DNA array resource supporting projects in this SPORE. The specifics of this core facility are: 1) To provide consultation at all stages of project development and experimentation using microarray techniques; 2) to provide synthesis and labeling of nucleic acid target for microarray experiments; 3) to provide custom array production; 4) to provide microarray hybridization, washing, staining, image analysis and data management services for projects of the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA092629-01
Application #
6547977
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-14
Project End
2006-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Audenet, François; Vertosick, Emily A; Fine, Samson W et al. (2018) Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. J Urol 199:961-968
Hugosson, Jonas; Godtman, Rebecka Arnsrud; Carlsson, Sigrid V et al. (2018) Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52:27-37
Kohestani, Kimia; Chilov, Marina; Carlsson, Sigrid V (2018) Prostate cancer screening-when to start and how to screen? Transl Androl Urol 7:34-45
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Kim, Kwanghee; Watson, Philip A; Lebdai, Souhil et al. (2018) Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clin Cancer Res 24:2408-2416
Assel, Melissa J; Gerdtsson, Axel; Thorek, Daniel L J et al. (2018) Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. Oncotarget 9:5778-5785
Ran, Leili; Chen, Yuedan; Sher, Jessica et al. (2018) FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discov 8:234-251

Showing the most recent 10 out of 505 publications